Growth Factor Receptors in Cancer
Growth factor signaling regulates numerous cellular processes, including differentiation, survival, migration, and proliferation. Alterations to growth factor signaling pathways contribute to cancer initiation, progression, angiogenesis, and metastasis. Several FDA-approved cancer therapeutics modulate growth factor signaling by inhibiting the activity of growth factor receptors. As cancer cells develop resistance mechanisms to growth factor receptor inhibition, further drug development will be needed to overcome these challenges.
Continued development of growth factor receptor inhibitors, either as single agents or in combination therapies, will help to overcome these challenges. Cayman offers a variety of tools and services to study growth factor receptor signaling and inhibition in both physiological and pathological contexts.
- Epidermal Growth Factor Receptors
- Vascular Endothelial Growth Factor Receptors
- Fibroblast Growth Factor Receptors
- Insulin-Like Growth Factor Receptors
- Platelet-Derived Growth Factor Receptors
- TGF-β Receptors
Kinase Inhibitor Screening Libraries
Consists of two plates with ~160 selective and non-selective kinase inhibitors. Targets more than 70 distinct kinases and kinase families, as well as numerous additional kinase isoforms and individual kinases within target families.
Consists of 11 plates with more than 850 selective and non-selective kinase inhibitors. Has greater coverage of individual kinases, kinase isoforms and mutants, and kinase families compared to Cayman’s Kinase Screening Library.
- Includes inhibitors of lipid, receptor and non-receptor tyrosine, serine/threonine, and dual specificity kinases
- Targets include the ROCK, ALK, GSK3, PKC, PDGFR, VEGFR, Src, MAPK, CDK, and PI3K families, among many others
|Cayman provides custom synthesis services and structure-based drug design services to assist you with SAR studies.|